Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study
| Autor: | Yasusada Miura, Atsushi Horiuchi, Masao Tomonaga, Shigeru Shirakawa, Ryuzo Ohno, Akira Shibata, Kensuke Usuki, Syozo Irino, Kiyoshi Takatsuki, Ikurou Kimura, Tsukasa Abe, Atsushi Kuramoto, Minoru Ohkuma, Tamotsu Matsuda, Yasuo Ikeda, Nakamura Toru, Tamotsu Miyazaki, Fumimaro Takaku, Takeo Nomura, Toru Masaoka, Hideaki Mizoguchi, Akira B. Miura, Tadami Nagao, Akio Urabe, Yoshiyuki Niho, Haruto Uchino, Yutaka Yoshida, Yousirou Niitsu, Nobuyuki Hamajima, Hidehiko Saitou |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Randomization business.industry medicine.medical_treatment Hematology Filgrastim medicine.disease Gastroenterology law.invention Granulocyte colony-stimulating factor Surgery Randomized controlled trial law Internal medicine Remission Induction Therapy medicine Absolute neutrophil count business Febrile neutropenia medicine.drug |
| Zdroj: | British Journal of Haematology. 116:103-112 |
| ISSN: | 0007-1048 |
| Popis: | Summary. To investigate the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in patients with acute myelogenous leukaemia, a multicentre randomized study was performed. From October 1993 to September 1996, 270 patients with newly diagnosed acute myelogenous leukaemia were randomized to G-CSF or control groups after remission induction therapy. The G-CSF group received G-CSF (Filgrastim) from 48 h after the completing chemotherapy until the absolute neutrophil count exceeded 1·5 × 109/l. The control group did not receive G-CSF unless severe infection occurred. There were 245 evaluable patients (120 and 125 in the G-CSF and control groups respectively). The complete remission rate was similar in the G-CSF and control groups (80·8% versus 76·8%), as was the 5-year probability of disease-free survival (34·5% versus 33·6%) and overall survival (42·7% versus 35·6%). Neutrophil recovery was significantly faster in the G-CSF group than in the control group (12 d versus 18 d, P = 0·0001). The median duration of febrile neutropenia was significantly shorter in the G-CSF group than in the control group (3 d versus 4 d, P = 0·0001). In conclusion, prophylactic administration of G-CSF after remission induction therapy for acute myelogenous leukaemia is safe and useful even in patients without infection on completing chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text